New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison

Table 2 Pharmacy cost assumptions within each therapeutic scenario by genotype

Therapeutic scenario	Genotype	Drug	Daily dosage	WAC 1 week	Number of weeks	Regimen cost per person	Regimen references
Standard of Care (SOC)^d	1	Peginterferon alpha-2a or peginterferon alpha-2b	180^a,b or 120 mcg/0.5 ml^a,b	$1441.60^e or $705.16^e	48	$122,401.44	[10, 14]
		Ribavirin	1200 mg^b,c	$90.30	48
		Boceprevir or telaprevir	2400 or 2250 mg	$1521.24^e or $5512.92^e	44 or 12
	2/3	Peginterferon alpha-2a or peginterferon alpha-2b	180^a,b or 120 mcg/0.5 ml^a,b	$1441.60^e or $705.16^e	24	$27,205.92	[10]
	2/3	Ribavirin	800 mg	$60.20	24	$27,205.92	[10]
All oral	1	Sofosbuvir	400 mg	$7083.33	12	$85,000	[44]
	1	Ledipasvir	90 mg	$7083.33	12	$85,000	[44]
	2	Sofosbuvir	400 mg	$7000	12	$85,083.60	[45]
	2	Ribavirin	1200 mg^b,c	$90.30	12	$85,083.60	[45]
	3	Sofosbuvir	400 mg	$7000	24	$170,167.20	[45]
	3	Ribavirin	1200 mg^b,c	$90.30	24	$170,167.20	[45]

WAC wholesale acquisition cost
^aWeekly administration
^bWeight-based regimens were calculated based on the average weight of an adult, combining males and females, in the United States (181 lbs) [46]
^cRibavirin cost was calculated based on the median WAC cost for a 200 mg capsule
^dDefined as interferon-based therapy that was considered SOC up to November 2013
^eWhen there was a choice between two drugs, half of the group was assigned to each drug

ISSN: 1478-7547